Disease · MONDO_0005105

melanoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. melanoma. Diseases, record MONDO_0005105. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005105

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: melanoma; Open Targets
Open Targets ID: MONDO_0005105; Open Targets
Other names: Naevocarcinoma, malignant melanoma, melanoma (disease), melanoma, malignant; Open Targets
Disease Ontology: DOID:1909; Disease Ontology
MeSH: D008545; MeSH
NCI Thesaurus: C3224; NCI Thesaurus
Orphanet: ORPHA:411533; Orphanet
Highest stage of its drugs: Approval, for 22 of its 589 drugs, from DailyMed, EMA Human Drugs, FDA, PMDA and TTD; Open Targets

Drugs589

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
IPILIMUMAB	CHEMBL1789844	Antibody	Approval	DailyMed, EMA Human Drugs, PMDA and TTD	246	242	242	Drugs and targets
NIVOLUMAB	CHEMBL2108738	Antibody	Approval	DailyMed, EMA Human Drugs, PMDA and TTD	239	233	233	Drugs and targets
PEMBROLIZUMAB	CHEMBL3137343	Antibody	Approval	EMA Human Drugs, PMDA and TTD	233	229	229	Drugs and targets
VEMURAFENIB	CHEMBL1229517	Small molecule	Approval	DailyMed, EMA Human Drugs, PMDA and TTD	81	77	77	Drugs and targets
TRAMETINIB	CHEMBL2103875	Small molecule	Approval	EMA Human Drugs and TTD	79	76	76	Drugs and targets
DABRAFENIB	CHEMBL2028663	Small molecule	Approval	EMA Human Drugs and TTD	74	71	71	Drugs and targets
DACARBAZINE	CHEMBL476	Small molecule	Approval	TTD	72	70	70	Drugs and targets
INTERFERON ALFA-2B	CHEMBL1201558	Protein	Approval	DailyMed, FDA and TTD	56	52	42	Drugs and targets
BINIMETINIB	CHEMBL3187723	Small molecule	Approval	DailyMed, EMA Human Drugs, PMDA and TTD	52	47	47	Drugs and targets
ENCORAFENIB	CHEMBL3301612	Small molecule	Approval	EMA Human Drugs, PMDA and TTD	45	42	42	Drugs and targets

1 to 10 of 589

See all 589 drugs

Targets429

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
KDR	Vascular endothelial growth factor receptor	22	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/3791	Drugs and targets
PDCD1	Programmed cell death protein 1	21	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Approval	https://conductscience.org/library/genes/5133	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	17	Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2324	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	17	Stem cell growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/3815	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	16	Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2321	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor	16	Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/5159	Drugs and targets
TUBA1A	Tubulin	16	Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Phase 3	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	16	Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Phase 3	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	16	Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Phase 3	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	16	Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Phase 3	https://conductscience.org/library/genes/7278	Drugs and targets

1 to 10 of 429

See all 429 targets

Trials1,589

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 52 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01307397	A Study of Vemurafenib in Participants With Metastatic Melanoma	Phase 3	3,219	2017-12-18	Malignant Melanoma	VEMURAFENIB	Its record names the disease	ClinicalTrials.gov
NCT00094653	MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma	Phase 3	1,783	2011-06-23	Melanoma, Metastases	IPILIMUMAB	Its record names the disease	ClinicalTrials.gov
NCT01274338	Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery	Phase 3	1,673	2021-05-27	Melanoma of Unknown Primary, Recurrent Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7	INTERFERON ALFA-2B, IPILIMUMAB	Its record names the disease	ClinicalTrials.gov
NCT05665595	A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)	Phase 3	1,594	2025-04-06	Melanoma	PEMBROLIZUMAB, VIBOSTOLIMAB	Its record names the disease	ClinicalTrials.gov
NCT01968109	An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors	Phase 1/2	1,482	2026-01-06	Neoplasms by Site	NIVOLUMAB, RELATLIMAB	Its record names the disease	ClinicalTrials.gov
NCT02506153	Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery	Phase 3	1,301	2024-08-27	Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma, Metastatic Mucosal Melanoma, Metastatic Non-Cutaneous Melanoma, Non-Cutaneous Melanoma, Recurrent Cutaneous Melanoma, Recurrent Mucosal Melanoma, Recurrent Non-Cutaneous Melanoma	INTERFERON ALFA-2B, IPILIMUMAB, PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT01295827	Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001)	Phase 1	1,260	2019-12-13	Cancer, Solid Tumor	PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00003641	High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma	Phase 3	1,150	2016-05-04	Melanoma (Skin)	INTERFERON ALFA-2B	Its record names the disease	ClinicalTrials.gov
NCT05002569	A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma	Phase 3	1,093	2026-01-08	Melanoma	NIVOLUMAB, RELATLIMAB	Its record names the disease	ClinicalTrials.gov
NCT02362594	Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)	Phase 3	1,019	2019-01-04	Melanoma	PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 1,589

See all 1,589 trials

Comparisons in its trials322

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Pembrolizumab/Vibostolimab vs Pembrolizumab: deaths from any cause	6 of 701	1 of 701	1,402	NCT05665595	Trial comparisons
Pembrolizumab/Vibostolimab vs Pembrolizumab: serious adverse events	109 of 698	57 of 700	1,398	NCT05665595	Trial comparisons
FDA Approved Regimen vs MK-3475 (Pembrolizumab): deaths from any cause	130 of 654	131 of 647	1,301	NCT02506153	Trial comparisons
FDA Approved Regimen vs MK-3475 (Pembrolizumab): serious adverse events	23 of 565	125 of 639	1,204	NCT02506153	Trial comparisons
Treatment 1 vs Treatment 2: deaths from any cause	86 of 547	76 of 546	1,093	NCT05002569	Trial comparisons
Dabrafenib+Trametinib (On-treatment) vs Dabrafenib+Trametinib (Post-treatment Follow-up): deaths from any cause	1 of 552	47 of 537	1,089	NCT03551626	Trial comparisons
Treatment 1 vs Treatment 2: serious adverse events	174 of 543	121 of 545	1,088	NCT05002569	Trial comparisons
Pembrolizumab vs Placebo: deaths from any cause	25 of 514	35 of 505	1,019	NCT02362594	Trial comparisons
Pembrolizumab vs Placebo: Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)	70 of 509	18 of 502	1,011	NCT02362594	Trial comparisons
Pembrolizumab vs Placebo: Number of Participants Who Experienced At Least 1 Adverse Event (AE)	475 of 509	453 of 502	1,011	NCT02362594	Trial comparisons

1 to 10 of 322

See all 322 comparisons in its trials

Papers from its trials803

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
42315253	RESULT	1	PubMed
40885529	RESULT	1	PubMed
40234093	RESULT	1	PubMed
40152791	RESULT	1	PubMed
39792482	RESULT	1	PubMed
39775043	RESULT	1	PubMed
39774795	RESULT	1	PubMed
39531423	RESULT	1	PubMed
39486411	RESULT	1	PubMed
39417680	RESULT	1	PubMed

1 to 10 of 803

See all 803 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005105

GET https://conductscience.org/api/diseases/v1/MONDO_0005105/drugs?page=2

API reference For AI assistants